Today: 29 April 2026
NatWest share price today: NWG slips as buyback ticks on and Barclays cools ahead of Feb results
9 January 2026
1 min read

NatWest share price today: NWG slips as buyback ticks on and Barclays cools ahead of Feb results

London, January 9, 2026, 11:38 GMT — Regular session

NatWest Group Plc (NWG.L) shares eased on Friday, down 0.3% at 642.4 pence, as investors weighed the pace of the bank’s buyback and a recent broker downgrade. The stock opened at 644.6p and has traded between 640.2p and 647.2p.

The drift matters because NatWest’s rally has turned capital returns into the main debate. Buybacks and dividends can lift earnings per share by shrinking the share count, but they hinge on how much surplus capital the bank can generate and keep.

The next big marker is close. NatWest is due to publish its 2025 annual results on Feb. 13, when it has said it will set guidance for 2026 and new targets for 2028.

In a filing on Thursday, NatWest said it bought back 799,553 shares on Jan. 8 at a volume-weighted average price of 640.21 pence, with prices ranging from 625.0p to 643.2p. It said the shares will be cancelled and that, after settlement, it would hold about 220.1 million shares in treasury, with roughly 8.00 billion in issue excluding treasury stock.

Barclays cut NatWest to “equalweight” from “overweight” on Wednesday and kept its price target at 700p, saying it would “pause for breath” after what it called a strong run since late-2023 lows. In the same sector note, it lifted its target on Lloyds to 120p from 100p.

NatWest closed up 1.9% on Thursday at £6.44, a day after sliding 4.3%, and it is still about 4% below its 52-week high of £6.74 hit on Jan. 6. The broader FTSE 100 was up around 0.4% on Friday morning, with investors also braced for U.S. payrolls data later in the day.

But the buyback is not a free lunch. Faster-than-expected rate cuts could squeeze lending margins, and a weaker economy would raise the risk of loan losses eating into capital that might otherwise go to payouts.

For now, traders will watch whether the shares hold above this week’s 640p lows, and they will look to Feb. 13 for any reset to guidance, targets and the pace of cash returns.

Stock Market Today

  • Energean Shifts Investment Outlook with New Angola Deal and Updated Price Targets
    April 29, 2026, 1:31 PM EDT. Energean's central fair value estimate nudged from £9.24 to £9.30, reflecting analyst adjustments amid evolving risks. Berenberg reduced price targets by 75 GBp and 15 GBp, citing concerns over project execution and valuation. Jefferies downgraded Energean in February, signaling caution over its risk-reward balance. Notably, Energean secured the safe restart of its Power FPSO vessel, resuming production after a temporary suspension due to geopolitical tensions in early 2026. The company also agreed to acquire Chevron's interests in offshore Angola blocks for US$260 million plus contingent payments, aiming to boost output and reserves. Investors face execution and valuation risks but gain fresh growth impetus from the Angola acquisition, positioning Energean at a pivotal point for portfolio consideration.

Latest article

General Dynamics Corporation Stock Jumps After Submarine Orders, Gulfstream Jets Lift 2026 Outlook

General Dynamics Corporation Stock Jumps After Submarine Orders, Gulfstream Jets Lift 2026 Outlook

29 April 2026
General Dynamics raised its 2026 profit outlook after first-quarter earnings and revenue topped estimates, sending shares up 10.9% to $347.72. The company reported $1.4 billion in operating earnings and $13.5 billion in revenue, with Marine Systems revenue up 21% on submarine programs. Orders reached $26.6 billion, pushing backlog to $130.8 billion. General Dynamics ended the quarter with $3.7 billion in cash.
Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

29 April 2026
Teva reported first-quarter adjusted earnings of 53 cents per share on $3.98 billion revenue, beating estimates as sales of Austedo, Ajovy, and Uzedy climbed. Shares jumped 11% in New York trading. The company agreed to buy Emalex Biosciences for $700 million upfront, adding a late-stage Tourette syndrome drug candidate. Global generics revenue fell 16% amid increased competition.
Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

29 April 2026
Silicon Motion reported first-quarter revenue of $342.1 million, up 105% from a year earlier, and forecast second-quarter sales above Wall Street estimates. Shares rose $45.09 to $194.27 in New York trading. The company cited strong demand for embedded storage controllers and AI-related enterprise storage. CEO Wallace Kou said its MonTitan SSD controller platform will enter volume production this quarter.
GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom
Previous Story

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

UK stock market today: FTSE100 rises as Glencore jumps on Rio takeover talks
Next Story

UK stock market today: FTSE100 rises as Glencore jumps on Rio takeover talks

Go toTop